Skip to content

Sedation Methods During Cataract Surgery

A Comparison of Midazolam vs. Midazolam/Ketamine for Conscious Sedation in Patients Undergoing Phacoemulsification Under Topical Anesthesia

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03054103
Enrollment
105
Registered
2017-02-15
Start date
2016-05-03
Completion date
2016-11-11
Last updated
2018-09-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cataract, Phacoemulsification

Keywords

ketamine, midazolam, sedation

Brief summary

Background: Phacoemulsification is the most common surgical procedure performed in the United States and European Union and sedation is commonly used during phacoemulsification to help alleviate patient anxiety and prevent the patient from interfering with the procedure. The investigators have administered ketamine in addition to midazolam in this regard. To study the effectiveness of this technique, The investigators proposed a study to determine if adding low-dose ketamine to midazolam has any beneficial (or negative) effects on operating conditions, patient satisfaction, and recovery during and after unilateral phacoemulsification procedures performed using topical anesthesia and intravenous (IV) conscious sedation. Methods: In a free-standing Outpatient Surgery Center, the investigators conducted a randomized, double-masked, 3-arm, prospective comparison of IV midazolam only vs. midazolam with ketamine 5 mg IV vs. midazolam with ketamine 10 mg IV. The investigators then measured a single surgeon's assessment of surgical conditions, self-reported patient satisfaction, postoperative pain score, and duration of postoperative stay. The investigators also analyzed the dose of midazolam required to meet subjective anxiolysis in each group.

Detailed description

Phacoemulsification is the most common surgical procedure performed in the United States and European Union. In addition, the number of diagnoses of cataracts is expected to double from 25,000,000 in 2010 to 50,000,000 in 2050 while the incidence of phacoemulsification is also increasing. Therefore, any attempt to optimize outcome and efficiency is significant. Sedation is commonly used during phacoemulsification to help alleviate patient anxiety and prevent the patient from interfering with the procedure. However, a great deal of variation exists in anesthetic management of these cases. Investigators have published use of a number of agents for sedation in the literature. These include midazolam, clonidine, propofol, fentanyl, dexmedetomidine, remifentanil, and oral diazepam. Intravenous (IV) clonidine has a half-life of 9-13 h and increased risk of postoperative hypotension. Propofol causes disinhibition and it has to be titrated during surgery to prevent oversedation. Opioids carry an increased risk of respiratory depression, prolonged sedation, as well as delirium in the elderly. Finally, oral medications do not allow for quick dose adjustments during surgery. Intravenous midazolam is commonly used for sedation during phacoemulsification and other minor procedures. It has properties as an anxiolytic, muscle relaxant, and it is effective at reducing intraocular pressure. However, anxious patients administered benzodiazepines may require higher doses during cataract surgery which can lead to oversedation or disinhibition with subsequent patient movement. These responses can reduce the patient's ability to follow simple commands which can affect surgical outcome. Additionally, patients who receive too much sedation may fall asleep and wake up startled, similarly compromising the outcome of the surgery. In the search for additional medications that can improve surgical conditions and patient comfort during phacoemulsification, the investigators explored the use of a medication that can improve analgesia and reduce patient movement during procedures, namely ketamine. Ketamine is an NMDA antagonist with both sedative and analgesic properties and has minimal effects on respiration. Ketamine has been used to premedicate and sedate patients undergoing day care procedures without adverse effects, and patients, typically, remain cooperative albeit being sedated. These properties along with its relatively short elimination half-life of 2 h (compared with 3-4 h for midazolam) make ketamine an attractive agent for sedation during monitored anesthesia care (MAC) for cataract surgery. The purpose of this study was to determine if adding low-dose ketamine to midazolam has any beneficial (or negative) effects on operating conditions, patient satisfaction, and recovery during and after unilateral phacoemulsification procedures performed using topical anesthesia and IV conscious sedation. The investigators measured the surgeon's assessment of the participant's cooperation during surgery according to a predetermined Likert scale. The investigators also recorded the following outcome measures regarding each participant's surgery: 1) total dose of midazolam, 2) average time spent in the procedural room, 3) postoperative length of stay (LOS), and 4) average postoperative pain score. The subjects received a survey inquiring about the subjects' comfort and sedation level during surgery. Finally, the investigators recorded the following demographic data for all participants: gender, age, psychiatric diagnoses, and use of CNS, psychiatric, or opioid medications. Statistical Analysis The investigators used Fisher's exact test for examining data expressed as percentages, and Students t-test for yes/no data, and repeated measures ANOVA for 3 group analysis (LOS, surgical duration). The investigators judged significance at a P-value of 0.05. The investigators utilized a generalized estimated equations (GEE) to fit a logistic model to assess differences in the responses of patients based on amount of ketamine received. The GEE approach can fit models to correlated outcomes, as in the case where subjects had more than one procedure performed.

Interventions

DRUGMidazolam + Ketamine 10 MG/ML: 0.5 ML

5 mg ketamine IV given just prior to onset of case. Then titrated midazolam up to 2 mg IV at beginning and during case.

DRUGMidazolam + Ketamine 10 MG/ML: 1 ML

10 mg ketamine IV given just prior to onset of case. Then titrated midazolam up to 2 mg IV at beginning and during case.

DRUGMidazolam + Normal saline

Preoperative control: Normal saline placebo given preoperatively. Then protocol followed for titration of midazolam up to 2 mg IV at beginning and during case.

Sponsors

Wake Forest University Health Sciences
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Outcomes Assessor)

Masking description

Surgical conditions and patient response not aware of medication given.

Intervention model description

Randomized, controlled, double-masked, three-armed clinical comparison

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* Patients met inclusion criteria if they were between 18- and 80-years-old and undergoing elective cataract surgery performed by a single ophthalmologist (KW).

Exclusion criteria

* Patients younger than 18, older than 80, those with a serum creatinine \>3 mg/dl, advanced liver disease (liver enzymes twice the normal range or higher), and those with an allergy to any of the study medications were excluded from the study.

Design outcomes

Primary

MeasureTime frameDescription
Eye Mobility During Surgery (See Link to Study Protocol for Scale)Intraoperative, end of operation reportedScale of mobility of eye during surgery rate 0 (no movement) to 3 (movement enough to stop surgery).

Secondary

MeasureTime frameDescription
Measure of Comfort (See Link to Study Protocol for Scale)Obtained on the first day after surgery during the subject's routine postoperative check in the Ophthalmology Clinic.Measure of comfort (0-3; 0=very comfortable to 3=extremely uncomfortable
PACU Length of StayThis will occur one time only, in a range of 20 to 30 minutes after the surgery is completed.This is obtained from the records as time spent in the PACU (Recovery Room) after surgery.
NauseaThis will occur from time of entry into PACU to time of departure after their surgery. (One time only, in a range of 20 to 30 minutes after surgery.Self-reported incidence of nausea. This will be assessed by asking the subjects once (just prior to discharge from the PACU) whether they experienced any nausea while they were in the PACU (Recovery Room) and will be a measurement of the count of participants that experienced nausea during this period

Participant flow

Participants by arm

ArmCount
Midazolam Alone
Drug: Titrated midazolam + normal saline placebo Normal saline: Preoperative control: Normal saline placebo given preoperatively. Then protocol followed for titration of midazolam up to 2 mg IV at beginning and during case.
41
Midazolam + Ketamine 5 mg
Drug: Ketamine 10 MG/ML: 0.5 ML Ketamine 10 MG/ML: 0.5 ML: 5 mg ketamine IV given just prior to onset of case. Then titrated midazolam up to 2 mg IV at beginning and during case.
29
Midazolam + Ketamine 10 mg
Drug: Ketamine 10 MG/ML: 1 ML Ketamine 10 MG/ML: 1 ML: 10 mg ketamine IV given just prior to onset of case. Then titrated midazolam up to 2 mg IV at beginning and during case.
35
Total105

Baseline characteristics

CharacteristicMidazolam + Ketamine 5 mgMidazolam + Ketamine 10 mgMidazolam AloneTotal
Age, Categorical
<=18 years
0 Participants0 Participants0 Participants0 Participants
Age, Categorical
>=65 years
21 Participants28 Participants31 Participants80 Participants
Age, Categorical
Between 18 and 65 years
8 Participants7 Participants10 Participants25 Participants
Age, Continuous69.1 years
STANDARD_DEVIATION 8.1
65.6 years
STANDARD_DEVIATION 9.8
70.4 years
STANDARD_DEVIATION 8.8
68 years
STANDARD_DEVIATION 9.1
Region of Enrollment
United States
29 Participants35 Participants41 Participants105 Participants
Sex: Female, Male
Female
13 Participants21 Participants19 Participants53 Participants
Sex: Female, Male
Male
16 Participants14 Participants22 Participants52 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
EG002
affected / at risk
deaths
Total, all-cause mortality
— / —— / —— / —
other
Total, other adverse events
0 / 410 / 290 / 35
serious
Total, serious adverse events
0 / 410 / 290 / 35

Outcome results

Primary

Eye Mobility During Surgery (See Link to Study Protocol for Scale)

Scale of mobility of eye during surgery rate 0 (no movement) to 3 (movement enough to stop surgery).

Time frame: Intraoperative, end of operation reported

ArmMeasureValue (MEAN)Dispersion
Midazolam AloneEye Mobility During Surgery (See Link to Study Protocol for Scale)1.39 units on a scaleStandard Deviation 0.63
Midazolam + Ketamine 5 mgEye Mobility During Surgery (See Link to Study Protocol for Scale)1.41 units on a scaleStandard Deviation 0.63
Midazolam + Ketamine 10 mgEye Mobility During Surgery (See Link to Study Protocol for Scale)1.31 units on a scaleStandard Deviation 0.63
Secondary

Measure of Comfort (See Link to Study Protocol for Scale)

Measure of comfort (0-3; 0=very comfortable to 3=extremely uncomfortable

Time frame: Obtained on the first day after surgery during the subject's routine postoperative check in the Ophthalmology Clinic.

ArmMeasureValue (MEAN)Dispersion
Midazolam AloneMeasure of Comfort (See Link to Study Protocol for Scale)1.29 units on a scaleStandard Deviation 0.62
Midazolam + Ketamine 5 mgMeasure of Comfort (See Link to Study Protocol for Scale)1.18 units on a scaleStandard Deviation 0.6
Midazolam + Ketamine 10 mgMeasure of Comfort (See Link to Study Protocol for Scale)1.17 units on a scaleStandard Deviation 0.59
Secondary

Nausea

Self-reported incidence of nausea. This will be assessed by asking the subjects once (just prior to discharge from the PACU) whether they experienced any nausea while they were in the PACU (Recovery Room) and will be a measurement of the count of participants that experienced nausea during this period

Time frame: This will occur from time of entry into PACU to time of departure after their surgery. (One time only, in a range of 20 to 30 minutes after surgery.

ArmMeasureValue (COUNT_OF_PARTICIPANTS)
Midazolam AloneNausea0 Participants
Midazolam + Ketamine 5 mgNausea0 Participants
Midazolam + Ketamine 10 mgNausea0 Participants
Secondary

PACU Length of Stay

This is obtained from the records as time spent in the PACU (Recovery Room) after surgery.

Time frame: This will occur one time only, in a range of 20 to 30 minutes after the surgery is completed.

ArmMeasureValue (MEAN)Dispersion
Midazolam AlonePACU Length of Stay19.2 MinutesStandard Deviation 7.7
Midazolam + Ketamine 5 mgPACU Length of Stay19.0 MinutesStandard Deviation 6.5
Midazolam + Ketamine 10 mgPACU Length of Stay20.1 MinutesStandard Deviation 10.7

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026